MAYO CLINIC
Q1 2024 Form 13-F
ROCHESTER, MINNESOTA
CIK 0001318153
· Institutional investment manager
$6.1M Reported Value Total
Reported value
$6.1M
Quarter over quarter
+6.4%
Holdings
5
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Paul A Gorman
Chief Investment Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2024 13F record
Q1 2024 13F filing summary
| Period of report | March 31, 2024 |
|---|---|
| Filed | May 13, 2024 |
| Form | 13F-HR |
| Reported value | $6.1M |
| Positions | 5 |
| Change in reported value | -62.1% |
| New positions | 1 |
| Exited positions | 3 |
| Position turnover | 50.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2024 13F
Filed Nov 12, 2024
|
3 | $2.9M |
|
Q2 2024 13F
Filed Aug 12, 2024
|
4 | $3.0M |
|
Q1 2024 13F
Filed May 13, 2024
|
5 | $6.1M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
7 | $16.2M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
9 | $51.9M |
|
Q2 2023 13F
Filed Aug 9, 2023
|
11 | $97.4M |
|
Q1 2023 13F
Filed May 5, 2023
|
13 | $121.8M |
|
Q4 2022 13F
Filed Jan 26, 2023
|
13 | $188.8M |
|
Q2 2021 13F
Filed Aug 12, 2021
|
9 | $90.4M |
|
Q1 2021 13F
Filed May 13, 2021
|
8 | $86.9M |
|
Q4 2020 13F
Filed Feb 11, 2021
|
9 | $83.1M |
|
Q3 2020 13F
Filed Nov 12, 2020
|
9 | $74.2M |
|
Q2 2020 13F
Filed Aug 13, 2020
|
8 | $104.5M |
|
Q1 2020 13F
Filed Apr 24, 2020
|
7 | $39.5M |
|
Q4 2019 13F
Filed Feb 12, 2020
|
8 | $88.2M |
Top 5 holdings · Q1 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ZNTL Zentalis Pharmaceuticals Inc. | $2.9M | 48.0% |
| 2 | ACWI MSCI ACWI ETF | $1.9M | 31.11% |
| 3 | CATX Perspective Therapeutics Inc. | $862.3K | 14.03% |
| 4 | NMTC Neuroone Medical Technologies | $218.1K | 3.55% |
| 5 | UNBX UNITY BIOTECHNOLOGY INC | $203.5K | 3.31% |
Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.